Skip to main content

Pythag Tech closes a $4.25m seed to let AI design cheaper cultivated meat processes

Pythag Tech raised a $4.25m seed led by Azolla Ventures to use AI on growth media, cell lines and bioprocessing, and licenses the recipes to producers.

Pythag Tech closes a $4.25m seed to let AI design cheaper cultivated meat processes

Pythag Tech, a New York company, announced a $4.25 million seed round on 22 October 2026. Azolla Ventures led it, with Endurance28 and other institutional investors joining. The company builds machine learning models on a proprietary biological dataset and uses them to design cheaper production processes for cultivated meat.

The approach is aimed at three cost drivers the company names explicitly: growth media, cell line development and bioprocessing. Models generate hypotheses from existing data, large scale physical experiments test them, and every result is folded back into the dataset so the next round of experiments is better targeted. Chief executive Sami Nabulsi and chief research and development officer Anne-Sophie Mertgen lead the team, which runs a lab in Melbourne according to Green Queen.

What Pythag sells is the process, not the product. It licenses optimised combinations of cells, growth media and bioreactor conditions to food companies, which then do the manufacturing. Because it is a technology provider it does not need its own novel food clearance, although Nabulsi told Green Queen the company intends to go through approval alongside its customers: “We think it's on us to get them through the regulatory process”. The seed money goes to automation equipment, a second lab planned in Thailand and hiring on both the wet lab and the AI side.

The timing is pointed. Green Queen puts cultivated meat startup funding at $74 million in 2025, down 49 per cent on the year before and a long way from the roughly $1.5 billion the field attracted at its peak four years earlier. Azolla Ventures co-founder and general partner Matthew Nordan framed the thesis around cost rather than novelty: “Cultivated meat can provide a solution, but only if it provides functional equivalence at lower cost.” His release cites a 55 per cent rise in global meat production per capita between 1970 and 2020, and a United States cattle herd at its lowest level since the 1950s. Nabulsi is careful about single data points: “Hitting one cost number is a short-term win.”

Why it matters for AgTech founders: this is a bet that the scarce asset in biomanufacturing is process knowledge, not plant. Three years ago the same ambition would have been funded as a factory, and most of those factories are now the reason the sector raised $74 million last year. A licensing company carries no fermenter depreciation, no construction risk and no novel food dossier of its own, and it can be useful to a customer long before anyone writes a capital expenditure cheque. The trade is strategic leverage: whoever owns the plant owns the margin, and process licences get renegotiated. For European founders in biologicals, cultivated protein or precision fermentation, the practical question is which part of the stack can be sold as know how in the next 18 months while the capital markets stay shut to capital expenditure, and whether the dataset built in that period is defensible enough to be worth more than the plant later.

Source: GlobeNewswire

Pythag Tech closes a $4.25m seed to let AI design cheaper cultivated meat processes

Azolla Ventures leads the round for the New York company that runs machine learning over its own wet lab results and licenses the resulting production recipes rather than making meat itself.

By Dirk Vandenhirtz

· AgTech AI · North America · 3 min

Pythag Tech, a New York company, announced a $4.25 million seed round on 22 October 2026. Azolla Ventures led it, with Endurance28 and other institutional investors joining. The company builds machine learning models on a proprietary biological dataset and uses them to design cheaper production processes for cultivated meat.

The approach is aimed at three cost drivers the company names explicitly: growth media, cell line development and bioprocessing. Models generate hypotheses from existing data, large scale physical experiments test them, and every result is folded back into the dataset so the next round of experiments is better targeted. Chief executive Sami Nabulsi and chief research and development officer Anne-Sophie Mertgen lead the team, which runs a lab in Melbourne according to Green Queen.

What Pythag sells is the process, not the product. It licenses optimised combinations of cells, growth media and bioreactor conditions to food companies, which then do the manufacturing. Because it is a technology provider it does not need its own novel food clearance, although Nabulsi told Green Queen the company intends to go through approval alongside its customers: “We think it's on us to get them through the regulatory process”. The seed money goes to automation equipment, a second lab planned in Thailand and hiring on both the wet lab and the AI side.

The timing is pointed. Green Queen puts cultivated meat startup funding at $74 million in 2025, down 49 per cent on the year before and a long way from the roughly $1.5 billion the field attracted at its peak four years earlier. Azolla Ventures co-founder and general partner Matthew Nordan framed the thesis around cost rather than novelty: “Cultivated meat can provide a solution, but only if it provides functional equivalence at lower cost.” His release cites a 55 per cent rise in global meat production per capita between 1970 and 2020, and a United States cattle herd at its lowest level since the 1950s. Nabulsi is careful about single data points: “Hitting one cost number is a short-term win.”

Why it matters for AgTech founders: this is a bet that the scarce asset in biomanufacturing is process knowledge, not plant. Three years ago the same ambition would have been funded as a factory, and most of those factories are now the reason the sector raised $74 million last year. A licensing company carries no fermenter depreciation, no construction risk and no novel food dossier of its own, and it can be useful to a customer long before anyone writes a capital expenditure cheque. The trade is strategic leverage: whoever owns the plant owns the margin, and process licences get renegotiated. For European founders in biologicals, cultivated protein or precision fermentation, the practical question is which part of the stack can be sold as know how in the next 18 months while the capital markets stay shut to capital expenditure, and whether the dataset built in that period is defensible enough to be worth more than the plant later.

Source: GlobeNewswire

Back to AgTech News